---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-101892"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:39:44.078411+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics achieves target enrollment of 92 patients in VIRAGE Phase 2b trial for VCN-01 in pancreatic cancer

## Summary
- Target enrollment of 92 evaluable patients (46 per arm) achieved across 15 sites in Spain and USA within 21 months.
- VCN-01 is a systemically-administered oncolytic adenovirus with FDA Orphan Drug and Fast Track Designations for metastatic PDAC.
- VCN-01 treatment arm: two IV doses (1x10^13 vp/patient) administered ~3 months apart, 7 days prior to gem/nab-paclitaxel cycles.
- Phase 1 data for single VCN-01 dose plus SoC (n=6): 83% overall response rate, median PFS 6.3 months, OS 20.8 months.
- Company plans regulatory engagements to discuss next steps, including potential interim data analysis.

## SEC filing metadata
- accession: 0001104659-24-101892
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924101892/0001104659-24-101892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924101892/tm2424516d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-101892
- JSON: https://secwatch.observer/filing/0001104659-24-101892.json
- Plain text: https://secwatch.observer/filing/0001104659-24-101892.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.